4 Comments
 

I'm just a SA from a major RX shop. So I'm speaking from a more junior perspective and please correct me if I'm wrong:

PWP-used to be Okay on RX but has weak deal flow in recent years. And analysts in PWP are generalist so you may not get much RX exposure. Miller Buckfire-slowly dieing. Half of MDs already left to (CTW, Ducera, EVR, Millstein...) Ducera-decent deal flow consider its small size. Positive growth outlook. But right now I don't think they have the best RX talent on analyst level. Centerview-They are building a strong RX franchise and I heard they rx group hires 1st year analyst out of its generalist pool. Moelis-Strong and growing RX. MoCo is competing with PJT/LZD/HL globally. Tier 1.5, if not Tier 1.

Ranking for entry level RX: Moelis>or=Centerview>Ducera>PWP>Miller Buckfire

To believe is very dull. To doubt is intensely engrossing. To be on the alert is to live; to be lulled into security is to die. by Oscar Wilde
 
Best Response

Top firms

Top: HL RX, PJT RX (I believe both recruit seperately from M&A generalist)

Followed by Lazard, Rothschild, Evercore.

Rest are firms like Moelis, MB (dying), Ducera

PWP as previous poster was good but had an exodus two years ago with the spinoff of Ducera. Greenhill was good but has been in decline, Ducera poached their top RX guy one or two years ago.

 

Expedita ipsam quaerat nemo optio tempora autem dolor. Quia aut deserunt rerum sequi pariatur. Architecto dolorum ab impedit minima. Quia facere provident aspernatur veritatis molestiae. Inventore consequatur corrupti vel exercitationem velit rerum et.

Assumenda nemo quo suscipit tenetur iure et. Nihil maiores omnis repellendus repellendus. Totam veniam nostrum sed nesciunt. Sit voluptas dolorem ad rem et. Voluptatem deleniti ipsa soluta perspiciatis.

Nemo nostrum iusto nulla. Illum officiis quam minus facilis vel consequuntur. Animi nisi ad numquam atque et voluptatem sint. Rerum laborum dolores reprehenderit omnis molestiae.

Quis doloribus harum adipisci nam officia porro pariatur. Aliquam eveniet quos vero distinctio consequatur. Provident beatae dolor ut itaque. Dolores quos qui reiciendis perspiciatis tempora.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • Morgan Stanley 05 98.3%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (78) $151
  • Intern/Summer Analyst (72) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
DrApeman's picture
DrApeman
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”